These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7054228)

  • 1. Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects.
    Bohannon NV; Lorenzi M; Grodsky GM; Karam JH
    J Clin Endocrinol Metab; 1982 Feb; 54(2):459-62. PubMed ID: 7054228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of glucagon secretion during a tolbutamide infusion in normal and noninsulin-dependent diabetic subjects.
    Pfeifer MA; Beard JC; Halter JB; Judzewitsch R; Best JD; Porte D
    J Clin Endocrinol Metab; 1983 Mar; 56(3):586-91. PubMed ID: 6337181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
    Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
    J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin response to glucagon with or without tolbutamide in normal and diabetic subjects.
    Chiba M; Ohneda A; Sakai T; Goto Y
    Tohoku J Exp Med; 1982 Feb; 136(2):169-75. PubMed ID: 7041329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tolbutamide and hepatic extraction of insulin and glucagon and hepatic glucose output in anesthetized dogs.
    Ishida T; Chou MC; Lewis RM; Hartley CJ; Entman M; Field JB
    Endocrinology; 1981 Aug; 109(2):443-50. PubMed ID: 7018888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Islet hormonal regulation of glucose turnover during exercise in type 1 diabetes.
    Shilo S; Sotsky M; Shamoon H
    J Clin Endocrinol Metab; 1990 Jan; 70(1):162-72. PubMed ID: 1967178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients.
    Mokuda O; Murakami I; Ikeda T; Tominaga M; Mashiba H
    Exp Clin Endocrinol; 1988 Aug; 91(3):265-70. PubMed ID: 3075183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Peptide reserve in insulin-dependent diabetes. Comparative responses to glucose, glucagon and tolbutamide.
    Mirel RD; Ginsberg-Fellner F; Horwitz DL; Rayfield EJ
    Diabetologia; 1980 Sep; 19(3):183-8. PubMed ID: 6997119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans.
    Peacey SR; Rostami-Hodjegan A; George E; Tucker GT; Heller SR
    J Clin Endocrinol Metab; 1997 May; 82(5):1458-61. PubMed ID: 9141533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of A and B cell functions by tolbutamide and arginine in the pancreas of thiamine-deficient rats.
    Rathanaswami P; Sundaresan R
    Biochem Int; 1989 Oct; 19(4):793-802. PubMed ID: 2695088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide versus insulin infusion.
    Lewis GF; Steiner G; Polonsky KS; Weller B; Zinman B
    J Clin Endocrinol Metab; 1994 Jul; 79(1):66-70. PubMed ID: 8027255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma insulin, C-peptide and glucagon concentrations in patients with insulin-independent diabetes treated with chlorpropamide.
    Frier BM; Ashby JP; Nairn IM; Baird JD
    Diabete Metab; 1981 Mar; 7(1):45-9. PubMed ID: 7016620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormalities of endogenous glucagon and insulin in unstable diabetes.
    Reynolds C; Molnar GD; Horwitz DL; Rubenstein AH; Taylor WF; Jiang NS
    Diabetes; 1977 Jan; 26(1):36-45. PubMed ID: 830563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of short term physiological elevations of plasma glucagon concentration on plasma triglyceride concentration in normal and diabetic man.
    Schade DS; Eaton RP
    Horm Metab Res; 1977 Jul; 9(4):253-7. PubMed ID: 892688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute suppressive effect of human growth hormone on insulin release induced by glucagon and tolbutamide in man.
    Adamson U; Cerasi E
    Diabete Metab; 1975 Mar; 1():51-6. PubMed ID: 1234067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A stimulatory effect of tolbutamide on the insulin-mediated glucose uptake in subjects with impaired glucose tolerance (IGT).
    Schulz B; Ratzmann KP; Heinke P; Besch W
    Exp Clin Endocrinol; 1983 Aug; 82(2):222-31. PubMed ID: 6354732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
    Gutniak M; Grill V; Efendić S
    J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon enhances the direct suppressive effect of insulin on hepatic glucose production in humans.
    Lewis GF; Vranic M; Giacca A
    Am J Physiol; 1997 Mar; 272(3 Pt 1):E371-8. PubMed ID: 9124541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.